Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.

Bernstein A, Mrowczynski OD, Greene A, Ryan S, Chung C, Zacharia BE, Glantz M.

J Neurosurg. 2019 Nov 1:1-6. doi: 10.3171/2019.8.JNS19643. [Epub ahead of print]

PMID:
31675726
2.

Management of low-grade glioma: a systematic review and meta-analysis.

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M.

Neurooncol Pract. 2019 Jul;6(4):249-258. doi: 10.1093/nop/npy034. Epub 2018 Aug 18. Review.

PMID:
31386075
3.

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.

Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O'Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS.

Clin Cancer Res. 2019 Oct 1;25(19):5799-5807. doi: 10.1158/1078-0432.CCR-19-0261. Epub 2019 Jul 18.

PMID:
31320597
4.

Editorial. When can we be positive about p values?

Glantz M, Brandmeir N.

J Neurosurg. 2019 Feb 8:1-6. doi: 10.3171/2018.10.JNS182494. [Epub ahead of print] No abstract available.

PMID:
30738404
5.

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.

Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, Glantz M, Groves MD, Lee EQ, Lin N, Raizer J, Rudà R, Weller M, Van den Bent MJ, Vogelbaum MA, Chang S, Wen PY, Soffietti R.

Neuro Oncol. 2019 May 6;21(5):571-584. doi: 10.1093/neuonc/noz012.

6.

The Honest Palm Sign: Detecting Incomplete Effort on Physical Examination.

Zoccoli C, Li CF, Black D, Smith DB, Sheehan J, Harbaugh RE, Glantz M.

World Neurosurg. 2019 Feb;122:e1354-e1358. doi: 10.1016/j.wneu.2018.11.047. Epub 2018 Nov 15.

PMID:
30448572
7.

Impact of an External Ventricular Drain Placement and Handling Protocol on Infection Rates: A Meta-Analysis and Single Institution Experience.

Sieg EP, Schlauderaff AC, Payne RA, Glantz MJ, Simon SD.

World Neurosurg. 2018 Jul;115:e53-e58. doi: 10.1016/j.wneu.2018.03.160. Epub 2018 Apr 3.

PMID:
29621608
8.

Interleukin-13 conjugated quantum dots for identification of glioma initiating cells and their extracellular vesicles.

Madhankumar AB, Mrowczynski OD, Patel SR, Weston CL, Zacharia BE, Glantz MJ, Siedlecki CA, Xu LC, Connor JR.

Acta Biomater. 2017 Aug;58:205-213. doi: 10.1016/j.actbio.2017.06.002. Epub 2017 Jun 3.

PMID:
28583903
9.

Number needed to treat for stroke thrombectomy based on a systematic review and meta-analysis.

Church EW, Gundersen A, Glantz MJ, Simon SD.

Clin Neurol Neurosurg. 2017 May;156:83-88. doi: 10.1016/j.clineuro.2017.03.005. Epub 2017 Mar 10. Review.

PMID:
28359980
10.

External ventricular drain practice variations: results from a nationwide survey.

Baum GR, Hooten KG, Lockney DT, Fargen KM, Turan N, Pradilla G, Murad GJA, Harbaugh RE, Glantz M; EVD Best Practice Team.

J Neurosurg. 2017 Nov;127(5):1190-1197. doi: 10.3171/2016.9.JNS16367. Epub 2017 Jan 13.

PMID:
28084912
11.

How to facilitate early diagnosis of CNS involvement in malignant lymphoma.

Korfel A, Nowosielski M, Pardo-Moreno J, Penalver FJ, Buda G, Bennani H, Costopoulos M, Le Garff-Tavernier M, Soussain C, Schmid M, Orfao JA, Glantz M.

Expert Rev Hematol. 2016 Nov;9(11):1081-1091. Epub 2016 Oct 21. Review.

PMID:
27677656
12.

Extent of Resection and Survival in Glioblastoma Multiforme-Reply.

Brown TJ, Glantz M.

JAMA Oncol. 2016 Nov 1;2(11):1509-1510. doi: 10.1001/jamaoncol.2016.3812. No abstract available.

PMID:
27684462
13.

Multi-modality management of craniopharyngioma: a review of various treatments and their outcomes.

Varlotto J, DiMaio C, Grassberger C, Tangel M, Mackley H, Pavelic M, Specht C, Sogge S, Nguyen D, Glantz M, Saw C, Upadhyay U, Moser R, Yunus S, Rava P, Fitzgerald T, Glanzman J, Sheehan J.

Neurooncol Pract. 2016 Sep;3(3):173-187. doi: 10.1093/nop/npv029. Epub 2015 Aug 30.

14.

Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.

Kalinina J, Ahn J, Devi NS, Wang L, Li Y, Olson JJ, Glantz M, Smith T, Kim EL, Giese A, Jensen RL, Chen CC, Carter BS, Mao H, He M, Van Meir EG.

Clin Cancer Res. 2016 Dec 15;22(24):6256-6265. Epub 2016 Jun 23.

15.

Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.

Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M.

JAMA Oncol. 2016 Nov 1;2(11):1460-1469. doi: 10.1001/jamaoncol.2016.1373. Review.

16.

The angular course of the median nerve in the distal forearm and its anatomical importance in preventing nerve injury in a modern era of carpal tunnel release.

Payne R, Nasralah Z, Sieg E, Rizk EB, Glantz M, Harbaugh K.

J Neurosurg. 2017 Mar;126(3):979-984. doi: 10.3171/2016.4.JNS152672. Epub 2016 Jun 10.

PMID:
27285545
17.

Hybrid Neurofibroma-Schwannoma.

Hussain NS, Specht CS, Frauenhoffer E, Glantz M, Harbaugh K.

Cureus. 2016 Mar 30;8(3):e548. doi: 10.7759/cureus.548.

18.

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.

Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ.

Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6. Review.

19.

Systematic Review and Meta-analysis of Chiropractic Care and Cervical Artery Dissection: No Evidence for Causation.

Church EW, Sieg EP, Zalatimo O, Hussain NS, Glantz M, Harbaugh RE.

Cureus. 2016 Feb 16;8(2):e498. doi: 10.7759/cureus.498.

20.

Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!

Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M.

J Clin Oncol. 2016 May 20;34(15):1829-30. doi: 10.1200/JCO.2015.65.0879. Epub 2016 Mar 21. No abstract available.

21.

Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.

Xiu J, Piccioni D, Juarez T, Pingle SC, Hu J, Rudnick J, Fink K, Spetzler DB, Maney T, Ghazalpour A, Bender R, Gatalica Z, Reddy S, Sanai N, Idbaih A, Glantz M, Kesari S.

Oncotarget. 2016 Apr 19;7(16):21556-69. doi: 10.18632/oncotarget.7722.

22.

An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies.

Baker MJ, Goldstein AM, Gordon PL, Harbaugh KS, Mackley HB, Glantz MJ, Drabick JJ.

J Med Genet. 2016 Nov;53(11):721-727. doi: 10.1136/jmedgenet-2015-103446. Epub 2016 Jan 21. Review.

PMID:
26794401
23.

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.

Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H.

Am J Clin Oncol. 2018 Feb;41(2):159-162. doi: 10.1097/COC.0000000000000247.

PMID:
26658237
24.

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.

Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY.

Cancer. 2016 Feb 15;122(4):582-7. doi: 10.1002/cncr.29798. Epub 2015 Nov 20.

25.

Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey.

Walbert T, Glantz M, Schultz L, Puduvalli VK.

J Neurooncol. 2016 Jan;126(2):337-45. doi: 10.1007/s11060-015-1973-0. Epub 2015 Oct 30.

26.

Distinguishing grade I meningioma from higher grade meningiomas without biopsy.

Varlotto J, Flickinger J, Pavelic MT, Specht CS, Sheehan JM, Timek DT, Glantz MJ, Sogge S, Dimaio C, Moser R, Yunus S, Fitzgerald TJ, Upadhyay U, Rava P, Tangel M, Yao A, Kanekar S.

Oncotarget. 2015 Nov 10;6(35):38421-8. doi: 10.18632/oncotarget.5376.

27.

HFE polymorphisms affect survival of brain tumor patients.

Lee SY, Slagle-Webb B, Sheehan JM, Zhu J, Muscat JE, Glantz M, Connor JR.

J Neurooncol. 2015 Mar;122(1):97-104. doi: 10.1007/s11060-014-1681-1. Epub 2014 Dec 10.

PMID:
25491948
28.

Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report.

Patel AS, Allen JE, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS.

Oncol Lett. 2014 Jun;7(6):2110-2112. Epub 2014 Mar 24.

29.

COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation.

Allen JE, Patel AS, Prabhu VV, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS.

Cancer Res. 2014 May 1;74(9):2385-90. doi: 10.1158/0008-5472.CAN-13-2660. Epub 2014 Mar 10.

30.

Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.

Yamaguchi Y, Shao Z, Sharif S, Du XY, Myles T, Merchant M, Harsh G, Glantz M, Recht L, Morser J, Leung LL.

J Biol Chem. 2013 Feb 1;288(5):3097-111. doi: 10.1074/jbc.M112.362954. Epub 2012 Nov 30.

31.

Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.

Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL.

J Neurooncol. 2012 Nov;110(2):257-64. doi: 10.1007/s11060-012-0964-7. Epub 2012 Aug 30. Erratum in: J Neurooncol. 2013 May;113(1):151. Olsen, Jeffery J [corrected to Olson, Jeffrey J].

PMID:
22932984
32.

Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.

Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS.

Oncotarget. 2011 Oct;2(10):752-60.

33.

Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study.

Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S.

J Neurosurg. 2011 Oct;115(4):730-6. doi: 10.3171/2011.5.JNS101768. Epub 2011 Jul 1.

PMID:
21721878
34.

Preliminary use of differential scanning calorimetry of cerebrospinal fluid for the diagnosis of glioblastoma multiforme.

Chagovetz AA, Jensen RL, Recht L, Glantz M, Chagovetz AM.

J Neurooncol. 2011 Dec;105(3):499-506. doi: 10.1007/s11060-011-0630-5. Epub 2011 Jul 1.

PMID:
21720810
35.

Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.

Alexandru D, Glantz MJ, Kim L, Chamberlain MC, Bota DA.

Cancer. 2011 Oct 1;117(19):4506-11. doi: 10.1002/cncr.26065. Epub 2011 Mar 28.

36.

Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.

Weston CL, Glantz MJ, Connor JR.

Fluids Barriers CNS. 2011 Mar 3;8(1):14. doi: 10.1186/2045-8118-8-14.

37.

Is brain the new bone marrow? Stem cells, cancer, and cognition: a working hypothesis.

Mohile NA, Zoccoli CM, Glantz M.

Neurology. 2011 Mar 29;76(13):1118-20. doi: 10.1212/WNL.0b013e318212a928. Epub 2011 Feb 23. No abstract available.

PMID:
21346222
38.

Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis.

Glantz MJ, Van Horn A, Fisher R, Chamberlain MC.

Cancer. 2010 Apr 15;116(8):1947-52. doi: 10.1002/cncr.24921.

39.

Statistical and trial design considerations in central nervous system prophylaxis studies.

Smith JA, Glantz M.

Semin Oncol. 2009 Aug;36(4 Suppl 2):S69-76. doi: 10.1053/j.seminoncol.2009.05.008. Review.

PMID:
19660685
40.

Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment.

Chamberlain MC, Glantz M, Groves MD, Wilson WH.

Semin Oncol. 2009 Aug;36(4 Suppl 2):S35-45. doi: 10.1053/j.seminoncol.2009.05.005. Review.

PMID:
19660682
41.

Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.

Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F.

Semin Oncol. 2009 Aug;36(4 Suppl 2):S25-34. doi: 10.1053/j.seminoncol.2009.05.004. Review.

PMID:
19660681
42.

Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay.

Glantz M, Kesari S, Recht L, Fleischhack G, Van Horn A.

Semin Oncol. 2009 Aug;36(4 Suppl 2):S17-24. doi: 10.1053/j.seminoncol.2009.05.003.

PMID:
19660679
43.

The science of prevention: novel strategies for and new insights into central nervous system prophylaxis in patients with cancer.

Glantz M, Recht L.

Semin Oncol. 2009 Aug;36(4 Suppl 2):S1. doi: 10.1053/j.seminoncol.2009.05.010. No abstract available.

PMID:
19660678
44.

Gender disparity in the rate of partner abandonment in patients with serious medical illness.

Glantz MJ, Chamberlain MC, Liu Q, Hsieh CC, Edwards KR, Van Horn A, Recht L.

Cancer. 2009 Nov 15;115(22):5237-42. doi: 10.1002/cncr.24577.

45.

To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.

Lim HY, Thiel E, Glantz MJ.

Curr Opin Oncol. 2008 Sep;20(5):495-501. doi: 10.1097/CCO.0b013e32830b829e. Review.

PMID:
19106650
46.

Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.

Chamberlain MC, Glantz MJ.

Neurosurgery. 2008 Oct;63(4):720-6; author reply 726-7. doi: 10.1227/01.NEU.0000325494.69836.51.

PMID:
18981882
47.

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB.

J Clin Oncol. 2008 Dec 1;26(34):5610-7. doi: 10.1200/JCO.2008.16.7510. Epub 2008 Nov 3.

PMID:
18981465
48.

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.

Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1069-76. doi: 10.1016/j.ijrobp.2008.05.068. Epub 2008 Oct 30.

PMID:
18977094
49.

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.

Melisko ME, Glantz M, Rugo HS.

Nat Clin Pract Oncol. 2009 Jan;6(1):25-33. doi: 10.1038/ncponc1243. Epub 2008 Oct 21. Review.

PMID:
18936791
50.

Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C.

Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ.

J Neurooncol. 2009 Feb;91(3):271-7. doi: 10.1007/s11060-008-9707-1. Epub 2008 Sep 27.

PMID:
18820836

Supplemental Content

Loading ...
Support Center